- Open Access
Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin
© Heller et al; licensee BioMed Central Ltd. 2008
- Received: 14 July 2008
- Accepted: 04 December 2008
- Published: 04 December 2008
Electroporation is an established technique for enhancing plasmid delivery to many tissues in vivo, including the skin. We have previously demonstrated efficient delivery of plasmid DNA to the skin utilizing a custom-built four-plate electrode. The experiments described here further evaluate cutaneous plasmid delivery using in vivo electroporation. Plasmid expression levels are compared to those after liposome mediated delivery.
Enhanced electrically-mediated delivery, and less extensively, liposome complexed delivery, of a plasmid encoding the reporter luciferase was tested in rodent skin. Expression kinetics and tissue damage were explored as well as testing in a second rodent model.
Experiments confirm that electroporation alone is more effective in enhancing reporter gene expression than plasmid injection alone, plasmid conjugation with liposomes followed by injection, or than the combination of liposomes and electroporation. However, with two time courses of multiple electrically-mediated plasmid deliveries, neither the levels nor duration of transgene expression are significantly increased. Tissue damage may increase following a second treatment, no further damage is observed after a third treatment. When electroporation conditions utilized in a mouse model are tested in thicker rat skin, only higher field strengths or longer pulses were as effective in plasmid delivery.
Electroporation enhances reporter plasmid delivery to the skin to a greater extent than the liposome conjugation method tested. Multiple deliveries do not necessarily result in higher or longer term expression. In addition, some impact on tissue integrity with respect to surface damage is observed. Pulsing conditions should be optimized for the model and for the expression profile desired.
- Reporter Expression
- Muscle Degeneration
- Plasmid Delivery
- Liposome Delivery
- Multiple Delivery
The skin is an attractive target for gene therapy protocols for cutaneous diseases, vaccines and several metabolic disorders because it is easily accessible for both delivery and monitoring. To fully take advantage of skin as a target for gene transfer, it is important to establish an efficient and reproducible delivery system. Electroporation as a tool for the delivery of plasmid DNA is a strong candidate to meet these delivery criteria. Electroporation-mediated cutaneous plasmid DNA delivery has been demonstrated by many groups [1, 2] for the eventual purpose of gene therapy.
Liposome or vesicle-complexed plasmid DNA has also been tested for enhancing transgene expression in the skin. Topical delivery has been performed in intact skin [3–9] and skin stripped of keratinocytes [10–12]. Intradermal injection of liposomes has been performed in a rat skin flap model . This delivery may induce an immune response and has therefore been tested in vaccine delivery [8–11] and delivery has also been performed for therapeutic purposes [3, 10, 13]. In the study presented here, reporter expression was observed after intradermal injection of liposome-complexed DNA alone and in combination with in vivo electroporation.
Electroporation (EP) is a physical method that enhances delivery of molecules to tissues in vivo. Confined electrical pulses are delivered to tissues at levels which increase cell permeability without killing the cells, enabling molecules to pass through the cell membrane. EP has been used to effectively deliver chemotherapeutic agents to tumors in animals and in humans  and plasmid DNA to a variety of tissues in both animals and humans .
Recent studies have shown that electroporation efficiently delivers plasmid DNA to the skin resulting in increased local and serum expression levels compared to injection alone [15–31]. Skin electroporation delivery has been successfully performed in rodent [15, 16, 18–22, 24, 26–32], rabbit , pig [16, 17, 23, 32] and non-human primate [16, 32] model systems.
Several studies have been designed to use electrically mediated plasmid delivery for vaccine purposes, including hepatitis B surface antigen [17, 22, 23, 25] and HIV . Electrically mediated plasmid delivery to the skin has also been tested therapeutically. Delivery of the gene encoding erythropoietin to the skin achieved significantly elevated serum levels as well as significantly elevated hematocrit compared to injection of plasmid without EP . Delivery of a plasmid encoding a growth factor [24, 28] or a transcription factor which controls growth factor expression  increased wound healing. These studies demonstrate the feasibility of using this approach therapeutically or for increasing serum levels of a specific protein.
Molecule delivery is more efficient when the field is applied in more than one direction [33–35]. With two plate electrodes, the electrode must be repositioned for the second set of pulses. Therefore, a non-invasive four-plate electrode (4PE) was developed to allow the application of two sets of pulses rotated 90° with respect to each other, which makes pulse application more straightforward . Delivery with this electrode results in reporter gene expression equivalent or superior to commercially available electrodes for delivery to the skin. The purpose of the experiments described here is to further investigate localized cutaneous plasmid delivery with the 4PE. Localized transgene expression levels and kinetics and histological damage were compared after the electrically mediated delivery of plasmid DNA. Delivery with the electrode was also tested in a larger rodent model, the rat.
Six to 7 week old female BALB/c mice (NCI) or 200–250 gram male Sprague Dawley rats were anesthetized in an induction chamber charged with 3% isoflurane in O2 then fitted with a standard rodent mask and kept under general anesthesia during treatment.
gWizLuc was commercially prepared (Aldevron, Fargo, ND). Endotoxin levels were < 0.1 EU/μg plasmid. For in vivo electroporation, 50 μl gWizLuc suspended to 2 μg/μl in sterile injectable saline was injected intradermally. Using a 4PE electrode , eight 100 V/cm 150 ms pulses at a frequency of 1 Hz were immediately applied with a BTX 830 pulse generator (BTX Molecular Delivery Systems, Holliston, MA) unless otherwise noted. For liposome delivery, 100 μg gWizLuc was complexed with a commercial preparation of DOTAP (N-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethyl-ammonium-methyl-sulfate, (Roche Diagnostics, Mannheim, Germany) in a ratio of 1:1.6 (w/w)  and 50 μl was injected intradermally.
Luciferase reporter assay
At the indicated time points after plasmid delivery, luciferase activity was quantified as previously described . The treated area was consistently 6 mm in diameter. However, since there was some variation in the diametric tissue excised, activity was expressed in total ng luciferase per treatment area. Values represent mean and standard error. Experiments containing only two groups were analyzed by Student's unpaired T test. Experiments with greater than two groups were analyzed by nonparametric ANOVA.
For histological analysis, 50 μl 2 μg/μl gWizLuc was delivered using eight 150 ms 100 V/cm pulses with the 4PE. At the time points indicated, the mice were euthanized and a seven mm diameter circle of skin 2–3 mm thick that encompassed the 6 mm diameter treatment area was removed. After fixation in 10% neutral buffered formalin for six hours, each sample was dehydrated in ascending grades of ethanol, cleared in xylene, and infiltrated with paraffin. Following embedding, tissues were cut into four 4 mm sections. Sections were stained with hematoxylin and eosin and then examined histologically for damage. Samples were graded using a schema including surface damage, inflammation, bullae, muscle degeneration and subepidermal necrosis in eight 4 × 7 mm sections . For surface damage, the percentage of each section damaged was determined. For the other damage assessments, any damage seen within a low power field (40×), even focal points, was considered positive. The percentage reported was the number of positive fields seen (eight fields per section and four sections per sample). The total amount of damage was determined for each sample and expressed as the mean and SEM of the percentage of the total treatment area. Significance was determined for the three groups by nonparametric ANOVA.
There are several possible reasons as to why the results of these three studies differ considerably. There are variations the lipid composition, the reporter gene delivered, the in vivo electroporation parameters, and the method of analysis (overall transgene expression vs. transfection efficiency). In addition, these studies used a tumor, rather than skin, model. Tumor cells typically divide more rapidly than skin cells. It is understood that both EP and liposomes can destabilize cell membranes and, in this particular case, perhaps the combination of the two is disruptive, leading to decreased cell survival and ultimately decreased expression. Alternatively, exposure of the liposomes to EP may release the DNA prior to contact with the membranes and reduce the transport of plasmid through the cell membrane which would also lead to reduced transgene expression.
Clearly, EP enhances skin expression after intradermal injection of plasmid DNA [15–23, 25, 26, 29]. After a single cutaneous delivery, significantly increased reporter expression has been demonstrated in rabbits for two days , in mice  and rats [18, 19, 26] to seven days, and in mice to approximately two weeks [22, 29]. The differences in levels and duration of expression may be due to the different models, plasmid constructs, electrodes, electroporation protocols, and methods of analysis used.
When deliveries were performed on days 0, 10, 20, a similar immediate increase in reporter expression to 5.7 ± 1.9 total ng luciferase was observed (Figure 3). Interestingly, no spike in expression was observed after the day 10 delivery. However, day 12 expression was significantly higher than injection alone. A small but insignificant spike in expression was observed 48 hours after the day 20 delivery, and a statistically significant difference was also observed at day 37. Similar to the first time course, these multiple deliveries did not significantly alter the time course of reporter expression from that of a single plasmid delivery .
Tissue damage after three deliveries on days 0, 2, and 4.
1.3 ± 0.5
14.2 ± 4.4**
9.5 ± 3.5
2.4 ± 1.9
11.0 ± 3.0**
10.7 ± 3.0*
68.1 ± 12.7
100 ± 0
75.0 ± 11.5
66.7 ± 11.2
95.8 ± 4.2
59.7 ± 10.3
4.2 ± 4.2
47.2 ± 11.2*
43.1 ± 13.7
4.2 ± 4.2
37.5 ± 6.5*
52.7 ± 13.1**
59.7 ± 12.0
97.9 ± 2.1*
72.2 ± 11.3
66.7 ± 9.4
95.8 ± 4.2
52.8 ± 11.6
8.3 ± 5.6
48.6 ± 10.7*
43.8 ± 13.8
12.5 ± 9.0
50.0 ± 10.7*
40.3 ± 13.5
Tissue damage after three deliveries on days 0, 10, and 20.
2.4 ± 0.9
0.5 ± 0.2
3.0 ± 1.2
3.8 ± 1.1
0.3 ± 0.2*
3.0 ± 1.1
68.0 ± 12.7
68.0 ± 9.3
95.8 ± 4.2
52.6 ± 11.8
95.8 ± 4.2**
77.8 ± 6.9
31.9 ± 14.1
8.3 ± 5.6
29.2 ± 13.2
12.7 ± 5.9
4.2 ± 4.2
23.6 ± 9.5
68.0 ± 12.7
48.6 ± 10.7
84.7 ± 9.0
55.1 ± 11.2
66.7 ± 11.2
79.2 ± 7.7
23.6 ± 12.88
12.5 ± 8.5
38.9 ± 14.1
25.9 ± 8.8
4.2 ± 4.2
16.7 ± 9.4
After deliveries on days 0, 2, and 4, EP significantly increased surface damage, bullae, and subdermal necrosis over plasmid injection alone at both 4 and 6 days (Table 1). This damage may be ameliorated by the presence of plasmid DNA. No delivery type significantly increased inflammation more than any other. At day 4, muscle degeneration was increased significantly over plasmid injection alone, but this degeneration was resolved by day 6.
In the longer time course, deliveries were performed at days 0, 10, and 20, while histological analysis was performed at days 12 and 22 (Table 2). In this time course, low levels of surface damage were observed, although a significant increase with EP alone was observed over plasmid injection alone at day 22. Inflammation was also increased with EP alone at this time point. No significant differences were observed between delivery types in bullae, muscle degeneration, or subepidermal necrosis.
Although damage is observed in each time course following the second delivery, this damage does not increase after the third delivery. While there were no obvious safety issues with repeat deliveries, the results presented here suggest that repeat administrations should not be performed at the same specific site.
Electroporation is an effective method for in vivo delivery of plasmid DNA [1, 2], and this approach is also an effective tool for cutaneous applications. As has been seen with other tissues, a variety of EP protocols ranging from short, high field strength to long, low field strength pulses as well as both invasive and surface electrodes have been tested. When developing a protocol for a skin based application, it is important to consider all of these variables as each will contribute to the levels and duration of expression obtained. Expression levels in response to delivery of plasmids encoding potentially toxic molecules such as cytokines should be tightly controlled with only short term expression. Expression after delivery of plasmids encoding potential vaccine candidates also may only require short-term expression. However, in the case of replacement of a defective protein such as Factor IX, long-term expression is desirable.
The results obtained in the current study demonstrated that a non-invasive surface electrode can be used to deliver plasmid DNA to the skin. Delivery was successful in both mice and rats. The highest expression levels in each species were obtained with different EP parameters. While this delivery method is safe, if an application is being developed that requires multiple administrations, it is advisable to not perform the repeat at the same exact site as the first administration. As has been seen with delivery to other tissues, EP is a safe and reliable method to obtain efficient and effective delivery of plasmid DNA.
Supported in part by research grants from the National Institutes of Health R21 DK055588 and R01 EB005441; from National Aeronautics and Space Association (NNJ05HE62G) and by the Center for Molecular Delivery at the University of South Florida. Genetronics, Inc donated the pulse generator used in this work.
- Heller LC, Heller R: In vivo electroporation for gene therapy. Hum Gene Ther. 2006, 17: 890-897. 10.1089/hum.2006.17.890.View ArticlePubMedGoogle Scholar
- Favard C, Dean DS, Rols MP: Electrotransfer as a non viral method of gene delivery. Curr Gene Ther. 2007, 7: 67-77. 10.2174/156652307779940207.View ArticlePubMedGoogle Scholar
- Badea I, Verrall R, Baca-Estrada M, Tikoo S, Rosenberg A, Kumar P, Foldvari M: In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes. J Gene Med. 2005, 7: 1200-1214. 10.1002/jgm.763.View ArticlePubMedGoogle Scholar
- Kim A, Lee EH, Choi SH, Kim CK: In vitro and in vivo transfection efficiency of a novel ultradeformable cationic liposome. Biomaterials. 2004, 25: 305-313. 10.1016/S0142-9612(03)00534-9.View ArticlePubMedGoogle Scholar
- Meykadeh N, Mirmohammadsadegh A, Wang Z, Basner-Tschakarjan E, Hengge UR: Topical application of plasmid DNA to mouse and human skin. J Mol Med. 2005, 83: 897-903. 10.1007/s00109-005-0669-x.View ArticlePubMedGoogle Scholar
- Raghavachari N, Fahl WE: Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles. J Pharm Sci. 2002, 91: 615-622. 10.1002/jps.10061.View ArticlePubMedGoogle Scholar
- Shi Z, Curiel DT, Tang DC: DNA-based non-invasive vaccination onto the skin. Vaccine. 1999, 17: 2136-2141. 10.1016/S0264-410X(98)00488-5.View ArticlePubMedGoogle Scholar
- Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, Gupta PN, Rawat A, Dubey P: Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm. 2005, 296: 80-86. 10.1016/j.ijpharm.2005.02.016.View ArticlePubMedGoogle Scholar
- Wang J, Hu JH, Li FQ, Liu GZ, Zhu QG, Liu JY, Ma HJ, Peng C, Si FG: Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex. Exp Dermatol. 2007, 16: 724-729. 10.1111/j.1600-0625.2007.00584.x.View ArticlePubMedGoogle Scholar
- Alexander MY, Akhurst RJ: Liposome-medicated gene transfer and expression via the skin. Hum Mol Genet. 1995, 4: 2279-2285. 10.1093/hmg/4.12.2279.View ArticlePubMedGoogle Scholar
- Watabe S, Xin KQ, Ihata A, Liu LJ, Honsho A, Aoki I, Hamajima K, Wahren B, Okuda K: Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine. 2001, 19: 4434-4444. 10.1016/S0264-410X(01)00194-3.View ArticlePubMedGoogle Scholar
- Yu WH, Kashani-Sabet M, Liggitt D, Moore D, Heath TD, Debs RJ: Topical gene delivery to murine skin. J Invest Dermatol. 1999, 112: 370-375. 10.1046/j.1523-1747.1999.00513.x.View ArticlePubMedGoogle Scholar
- Liu PY, Wang XT, Badiavas E, Rieger-Christ K, Tang JB, Summerhayes I: Enhancement of ischemic flap survival by prefabrication with transfer of exogenous PDGF gene. J Reconstr Microsurg. 2005, 21: 273-279. 10.1055/s-2005-871755.View ArticlePubMedGoogle Scholar
- Electrochemotherapy, Electrogenetherapy, and Transdermal Drug Delivery – Electrically Mediated Delivery of Molecules to Cells. 2000, Totowa, NJ: Humana PressGoogle Scholar
- Titomirov AV, Sukharev S, Kistanova E: In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta. 1991, 1088: 131-4.View ArticlePubMedGoogle Scholar
- Glasspool-Malone J, Somiari S, Drabick JJ, Malone RW: Efficient nonviral cutaneous transfection. Mol Ther. 2000, 2: 140-6. 10.1006/mthe.2000.0107.View ArticlePubMedGoogle Scholar
- Drabick JJ, Glasspool-Malone J, King A, Malone RW: Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther. 2001, 3: 249-255. 10.1006/mthe.2000.0257.View ArticlePubMedGoogle Scholar
- Maruyama H, Ataka K, Higuchi N, Sakamoto F, Gejyo F, Miyazaki J: Skin-targeted gene transfer using in vivo electroporation. Gene Ther. 2001, 8: 1808-12. 10.1038/sj.gt.3301604.View ArticlePubMedGoogle Scholar
- Dujardin N, Van Der SP, Preat V: Topical gene transfer into rat skin using electroporation. Pharm Res. 2001, 18: 61-66. 10.1023/A:1011026726938.View ArticlePubMedGoogle Scholar
- Heller R, Schultz J, Lucas ML, Jaroszeski MJ, Heller LC, Gilbert RA, Moelling K, Nicolau C: Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol. 2001, 20: 381-10.1089/10445490150504666.View ArticleGoogle Scholar
- Chesnoy S, Huang L: Enhanced cutaneous gene delivery following intradermal injection of naked DNA in a high ionic strength solution. Mol Ther. 2002, 5: 57-62. 10.1006/mthe.2001.0511.View ArticlePubMedGoogle Scholar
- Zhang L, Nolan E, Kreitschitz S, Rabussay DP: Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochimica et Biophysica Acta-General Subjects. 2002, 1572: 1-9. 10.1016/S0304-4165(02)00270-2.View ArticleGoogle Scholar
- Babiuk S, Baca-Estrada ME, Foldvari M, Baizer L, Stout R, Storms M, Rabussay D, Widera G, Babiuk L: Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther. 2003, 8: 992-998. 10.1016/j.ymthe.2003.09.008.View ArticlePubMedGoogle Scholar
- Marti G, Ferguson M, Wang J, Byrnes C, Dieb R, Qaiser R, Bonde P, Duncan MD, Harmon JW: Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model. Gene Ther. 2004Google Scholar
- Medi BM, Hoselton S, Marepalli RB, Singh J: Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. Int J Pharm. 2005, 294: 53-63. 10.1016/j.ijpharm.2004.12.014.View ArticlePubMedGoogle Scholar
- Pavselj N, Preat V: DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. J Control Release. 2005, 106: 407-415. 10.1016/j.jconrel.2005.05.003.View ArticlePubMedGoogle Scholar
- Thanaketpaisarn O, Nishikawa M, Yamashita F, Hashida M: Tissue-specific characteristics of in vivo electric gene: transfer by tissue and intravenous injection of plasmid DNA. Pharm Res. 2005, 22: 883-891. 10.1007/s11095-005-4583-2.View ArticlePubMedGoogle Scholar
- Lin MP, Marti GP, Dieb R, Wang J, Ferguson M, Qaiser R, Bonde P, Duncan MD, Harmon JW: Delivery of plasmid DNA expression vector for keratinocyte growth factor-1 using electroporation to improve cutaneous wound healing in a septic rat model. Wound Repair Regen. 2006, 14: 618-624. 10.1111/j.1743-6109.2006.00169.x.View ArticlePubMedGoogle Scholar
- Heller LC, Jaroszeski MJ, Coppola D, Mccray AN, Hickey J, Heller R: Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther. 2007, 14: 275-280. 10.1038/sj.gt.3302867.PubMed CentralView ArticlePubMedGoogle Scholar
- Vandermeulen G, Staes E, Vanderhaeghen ML, Bureau MF, Scherman D, Preat V: Optimisation of intradermal DNA electrotransfer for immunisation. J Control Release. 2007, 124: 81-87. 10.1016/j.jconrel.2007.08.010.View ArticlePubMedGoogle Scholar
- Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV, Nastai M, Semenza GL, Harmon JW: Age-dependent impairment of HIF-1alpha expression in diabetic mice: Correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol. 2008, 217: 319-327. 10.1002/jcp.21503.PubMed CentralView ArticlePubMedGoogle Scholar
- Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB: Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine. 2008, 26: 440-448. 10.1016/j.vaccine.2007.10.041.View ArticlePubMedGoogle Scholar
- Gilbert RA, Jaroszeski MJ, Heller R: Novel electrode designs for electrochemotherapy. Biochim Biophys Acta. 1997, 1334: 9-14.View ArticlePubMedGoogle Scholar
- Sersa G, Cemazar M, Semrov D, Miklavcic D: Changing electrode orientation improves the efficacy of electrochemotherapy of solid tumors in mice. Bioelectrochem Bioenerg. 1996, 39: 61-66. 10.1016/0302-4598(95)01866-2.View ArticleGoogle Scholar
- Faurie C, Phez E, Golzio M, Vossen C, Lesbordes JC, Delteil C, Teissie J, Rols MP: Effect of electric field vectoriality on electrically mediated gene delivery in mammalian cells. Biochim Biophys Acta. 2004, 1665: 92-100. 10.1016/j.bbamem.2004.06.018.View ArticlePubMedGoogle Scholar
- Heller L, Jaroszeski MJ, Coppola D, Pottinger C, Gilbert R, Heller R: Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo. Gene Therapy. 2000, 7: 826-829. 10.1038/sj.gt.3301173.View ArticlePubMedGoogle Scholar
- Wells JM, Li LH, Sen A, Jahreis GP, Hui SW: Electroporation-enhanced gene delivery in mammary tumors. Gene Ther. 2000, 7: 541-7. 10.1038/sj.gt.3301141.View ArticlePubMedGoogle Scholar
- Cemazar M, Sersa G, Wilson J, Tozer GM, Hart SL, Grosel A, Dachs GU: Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther. 2002, 9: 399-406. 10.1038/sj.cgt.7700454.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.